Portfolio Lab

CareDx, Inc.

  • Stock
  • Ticker CDNA
  • ISIN US14167L1035
  • Nasdaq

Health care · Health care services · USA

$70.00 −2.67%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of CareDx, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

CDNAGlobal equities (VT)

$10,000 grew to $233,333. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −94.9% in 10/2023, measured from the peak in 01/2021. The old peak has not been reached again yet.

1-year return
+344.2%
5-year return p.a.
+10.2%
10-year return p.a.
+37.0%
Volatility p.a.
86.8%
Largest decline
−94.9%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue878587100108118132139
Operating income84-13-11-0.2-6.01.21138.1
EBITDA88-9.8-7.43.6-2.25.111615
Net income88-10-8.61.7-4.12.811119
Earnings per share1.60-0.19-0.160.03-0.080.052.070.35
Balance sheet
Total assets491490444432413411533641
Liabilities11311011712111098107174
Equity378379327311303314426467
Cash1158968916578374250
Cash flow
Operating cash flow22-279.937214.33113
Capital expenditure–-1.6-1.0-1.3–-3.8-1.9-1.6
Free cash flow22-288.936210.52911

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2018 at +242.5%, weakest 2022 at −74.9%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
29 Oct 2026$0.35
30 Jul 2026$2.07
28 Apr 2026$0.05
25 Feb 2026−$0.08
4 Nov 2025$0.03
6 Aug 2025−$0.16
30 Apr 2025−$0.19
28 Feb 2025$1.60
4 Nov 2024−$0.20
31 Jul 2024−$0.09
9 May 2024−$0.38
28 Feb 2024−$2.20

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€3.3bn
Market cap in trading currency
$3.68bn
Enterprise value
$3.43bn
P/E
29.3
P/S
7.39
P/B
7.87
EV/Sales
6.89
EV/EBITDA
25.5
Earnings yield
3.4%
FCF yield
1.9%

Results (last four quarters)

Revenue
$497m
Gross profit
–
EBITDA
$134m
Net income
$129m
Earnings per share
$2.39
Revenue per share
$9.47
Revenue growth
+39.3%
Earnings growth
+1,051.8%

Profitability

Gross margin
–
Operating margin
23.4%
Net margin
25.9%
Return on equity
33.0%
Return on assets
20.1%

Balance sheet and cash flow

Cash
$250m
Cash per share
$4.77
Financial debt
–
Debt/equity %
–
Current ratio
2.31
Book value per share
$8.90
Operating cash flow
$69.0m
Free cash flow
$69.0m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
52.5m
Volume
780,998
Avg. volume 3 months
1.33m
Relative volume
0.6

Price and technicals

Price
$70.00
1 day
−2.7%
52-week high
$88.47
52-week low
$15.76
Distance to 52-week high
−20.9%
Distance to 52-week low
+344.2%
Distance to 50-day line
+2.0%
Distance to 200-day line
+84.0%
RSI (14)
44
Volatility 1M
94.7%

Performance

1 week
−10.1%
1 month
+1.2%
3 months
+47.4%
6 months
+223.6%
YTD
+271.5%
1 year
+338.0%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has CDNA performed since 11/2016?

$10,000 grew to $233,333 by 20 Nov 2026, which is +37.0% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is CDNA?

Volatility was 86.8% per year, measured on monthly returns. The largest decline from a peak was −94.9%, with the low in 10/2023.

How does CDNA compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, CDNA returned +37.0% at 86.8%. The correlation of monthly returns was 0.28; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

CareDx, Inc. (CDNA): Return and risk | Portfolio Lab